{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "26265479", "DateCompleted": {"Year": "2016", "Month": "06", "Day": "07"}, "DateRevised": {"Year": "2024", "Month": "05", "Day": "18"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2015", "Month": "08", "Day": "12"}], "ELocationID": ["21", "10.1186/s40360-015-0021-1"], "Journal": {"ISSN": "2050-6511", "JournalIssue": {"Volume": "16", "PubDate": {"Year": "2015", "Month": "Aug", "Day": "12"}}, "Title": "BMC pharmacology & toxicology", "ISOAbbreviation": "BMC Pharmacol Toxicol"}, "ArticleTitle": "Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial.", "Pagination": {"StartPage": "21", "MedlinePgn": "21"}, "Abstract": {"AbstractText": ["The ozone challenge model can be used to assess the efficacy of anti-inflammatory compounds in early phases of clinical drug development. PUR118, a calcium salt based formulation engineered in the iSPERSE(TM) dry powder delivery technology, is a novel anti-inflammatory drug for COPD. Here we evaluated the efficacy and safety of three doses of PUR118 in attenuating ozone-induced airway inflammation in healthy volunteers.", "In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.", "Sputum neutrophils, sputum CD14+ cells, as well as concentrations of IL1B, IL6, IL8, MMP9, and TNFA in sputum supernatant significantly increased after ozone exposure (n = 24). The percentage of sputum neutrophils (n = 12 who completed all treatments) did not change following treatment with different doses of PUR118. The high dose treatment group (n = 16) showed a decrease in the percentage and number of sputum macrophages (p \u2264 0.05) as well as a decrease in blood neutrophils (p = 0.04), and an increase in blood CD14\u2009+ cells (p = 0.04) compared to baseline. All dosages of PUR118 were safe and well tolerated.", "Ozone challenge resulted in the expected and significant increase of sputum inflammatory parameters. Treatment with multiple rising doses of PUR118 was safe and three applications within 25 h prior to the ozone challenge had small effects on ozone-induced airway inflammation.", "ClinicalTrials.gov: NCT01690949. Registered 12 September 2012."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine, 30625, Hannover, Germany. olaf.holz@item.fraunhofer.de."}, {"Identifier": [], "Affiliation": "Member of the German Center for Lung Research (BREATH), Hannover, Germany. olaf.holz@item.fraunhofer.de."}], "LastName": "Holz", "ForeName": "Olaf", "Initials": "O"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine, 30625, Hannover, Germany."}], "LastName": "Biller", "ForeName": "H", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine, 30625, Hannover, Germany."}], "LastName": "Mueller", "ForeName": "M", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pulmatrix, Inc., Lexington, MA, USA."}], "LastName": "Kane", "ForeName": "K", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pulmatrix, Inc., Lexington, MA, USA."}], "LastName": "Rosano", "ForeName": "M", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pulmatrix, Inc., Lexington, MA, USA."}], "LastName": "Hanrahan", "ForeName": "J", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pulmatrix, Inc., Lexington, MA, USA."}], "LastName": "Hava", "ForeName": "D L", "Initials": "DL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine, 30625, Hannover, Germany."}, {"Identifier": [], "Affiliation": "Member of the German Center for Lung Research (BREATH), Hannover, Germany."}], "LastName": "Hohlfeld", "ForeName": "J M", "Initials": "JM"}], "DataBankList": [{"DataBankName": "ClinicalTrials.gov", "AccessionNumberList": ["NCT01690949"]}], "PublicationTypeList": ["Clinical Trial, Phase I", "Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "BMC Pharmacol Toxicol", "NlmUniqueID": "101590449", "ISSNLinking": "2050-6511"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Biomarkers"}, {"RegistryNumber": "0", "NameOfSubstance": "CXCL8 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Calcium Compounds"}, {"RegistryNumber": "0", "NameOfSubstance": "IL1B protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "IL6 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-1beta"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-6"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-8"}, {"RegistryNumber": "0", "NameOfSubstance": "Lactates"}, {"RegistryNumber": "0", "NameOfSubstance": "Lipopolysaccharide Receptors"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Necrosis Factor-alpha"}, {"RegistryNumber": "2URQ2N32W3", "NameOfSubstance": "calcium lactate"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "EC 3.4.24.35", "NameOfSubstance": "MMP9 protein, human"}, {"RegistryNumber": "EC 3.4.24.35", "NameOfSubstance": "Matrix Metalloproteinase 9"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Administration, Inhalation"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["administration & dosage", "adverse effects", "pharmacology", "therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": ["metabolism"], "DescriptorName": "Biomarkers"}, {"QualifierName": ["administration & dosage", "adverse effects", "pharmacology", "therapeutic use"], "DescriptorName": "Calcium Compounds"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemically induced", "prevention & control"], "DescriptorName": "Inflammation"}, {"QualifierName": ["metabolism"], "DescriptorName": "Interleukin-1beta"}, {"QualifierName": ["metabolism"], "DescriptorName": "Interleukin-6"}, {"QualifierName": ["metabolism"], "DescriptorName": "Interleukin-8"}, {"QualifierName": ["administration & dosage", "adverse effects", "pharmacology", "therapeutic use"], "DescriptorName": "Lactates"}, {"QualifierName": ["immunology"], "DescriptorName": "Lipopolysaccharide Receptors"}, {"QualifierName": ["drug effects", "immunology"], "DescriptorName": "Macrophages"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["metabolism"], "DescriptorName": "Matrix Metalloproteinase 9"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["drug effects"], "DescriptorName": "Neutrophils"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Ozone"}, {"QualifierName": ["drug effects"], "DescriptorName": "Respiratory System"}, {"QualifierName": [], "DescriptorName": "Single-Blind Method"}, {"QualifierName": ["metabolism"], "DescriptorName": "Tumor Necrosis Factor-alpha"}, {"QualifierName": [], "DescriptorName": "Young Adult"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. -http://www.goldcopd.com/. 2010.", "ArticleIdList": ["0"]}, {"Citation": "Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165\u20131185. doi: 10.1183/09031936.00128008.", "ArticleIdList": ["10.1183/09031936.00128008", "19407051"]}, {"Citation": "Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22:672\u2013688. doi: 10.1183/09031936.03.00040703.", "ArticleIdList": ["10.1183/09031936.03.00040703", "14582923"]}, {"Citation": "Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12:543\u2013559. doi: 10.1038/nrd4025.", "ArticleIdList": ["10.1038/nrd4025", "23977698"]}, {"Citation": "Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D, et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2008;21:616\u201323.", "ArticleIdList": ["18374614"]}, {"Citation": "Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62:1081\u20137.", "ArticleIdList": ["PMC2094292", "17573446"]}, {"Citation": "Hava DL, Kenyon J, Woodman P, Spicer D, Okerholm P, Wright P, et al. Reduced neutrophilic airway inflammation by inhalation of dry powder calcium salts in a mouse model of sub-chronic tobacco smoke exposure. Am J Respir Crit Care Med. 2012;185:A2274."}, {"Citation": "Hava DL, Woodman P, Spicer D, Kenyon J, Okerholm P, Wright P, et al. Inhaled calcium salts reduce acute airway inflammation associated with tobacco smoke exposure. Am J Respir Crit Care Med. 2011;183:A2555."}, {"Citation": "Watanabe W, Thomas M, Clarke R, Klibanov AM, Langer R, Katstra J, et al. Why inhaling salt water changes what we exhale. J Colloid Interface Sci. 2007;307:71\u20138.", "ArticleIdList": ["17161415"]}, {"Citation": "DeHaan W, Clarke RW, Trautman BG, Clarke TC, Sabater JR, Abraham WM. Inhaled calcium based dry powder enhances whole lung mucociliary clearance in sheep. Am J Respir Crit Care Med. 2012;185:A2862."}, {"Citation": "Hava DL, Prasse A, Jewell N, Brogan T, Ku A, Manzanedo D, et al. Inhaled cationic salts inhibit infection of multiple viral pathogens and prevent influenza infection in vivo. Am J Respir Crit Care Med. 2011;183:A3369."}, {"Citation": "Holz O, Tal-Singer R, Kanniess F, Simpson KJ, Gibson A, Vessey RS, et al. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol. 2005;45:498\u2013503.", "ArticleIdList": ["15831772"]}, {"Citation": "Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J. 2010;35:564\u201370.", "ArticleIdList": ["19643947"]}, {"Citation": "Biller H, Holz O, Windt H, Koch W, M\u00fcller M, Jorres RA, et al. Breath profiles by electronic nose correlate with systemic markers but not ozone response. Respir Med. 2011;105:1352\u201363.", "ArticleIdList": ["21439804"]}, {"Citation": "Kirsten A, Watz H, Kretschmar G, Pedersen F, Bock D, Meyer-Sabellek W, et al. Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects--a double blind, randomized, placebo-controlled, cross-over clinical trial. Pulm Pharmacol Ther. 2011;24:555\u20138.", "ArticleIdList": ["21514398"]}, {"Citation": "Holz O, Richter K, J\u00f6rres RA, Speckin P, M\u00fccke M, Magnussen H. Changes in sputum composition between two inductions performed on consecutive days. Thorax. 1998;53:83\u201386. doi: 10.1136/thx.53.2.83.", "ArticleIdList": ["10.1136/thx.53.2.83", "PMC1758709", "9624289"]}, {"Citation": "Janssen O, Schaumann F, Holz O, Lavae-Mokhtari B, Welker L, Winkler C, et al. Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development. BMC Pulm Med. 2013;13:19.", "ArticleIdList": ["PMC3635929", "23537365"]}, {"Citation": "Widdicombe JH, Bastacky SJ, Wu DX, Lee CY. Regulation of depth and composition of airway surface liquid. Eur Respir J. 1997;10:2892\u20132897. doi: 10.1183/09031936.97.10122892.", "ArticleIdList": ["10.1183/09031936.97.10122892", "9493680"]}, {"Citation": "Grubor B, Meyerholz DK, Ackermann MR. Collectins and cationic antimicrobial peptides of the respiratory epithelia. Vet Pathol. 2006;43:595\u2013612. doi: 10.1354/vp.43-5-595.", "ArticleIdList": ["10.1354/vp.43-5-595", "PMC2786072", "16966437"]}, {"Citation": "Crowther RS, Marriott C, James SL. Cation induced changes in the rheological properties of purified mucus glycoprotein gels. Biorheology. 1984;21:253\u2013263.", "ArticleIdList": ["6466792"]}, {"Citation": "Kishioka C, Okamoto K, Kim JS, Rubin BK. Hyperosmolar solutions stimulate mucus secretion in the ferret trachea. Chest. 2003;124:306\u2013313. doi: 10.1378/chest.124.1.306.", "ArticleIdList": ["10.1378/chest.124.1.306", "12853538"]}, {"Citation": "Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science. 2000;287:1046\u20131049. doi: 10.1126/science.287.5455.1046.", "ArticleIdList": ["10.1126/science.287.5455.1046", "10669417"]}, {"Citation": "Colvin RA, Means TK, Diefenbach TJ, Moita LF, Friday RP, Sever S, et al. Synaptotagmin-mediated vesicle fusion regulates cell migration. Nat Immunol. 2010;11:495\u2013502.", "ArticleIdList": ["PMC2951881", "20473299"]}, {"Citation": "Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42:307\u2013313. doi: 10.1002/ppul.20594.", "ArticleIdList": ["10.1002/ppul.20594", "17352404"]}, {"Citation": "Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM, et al. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med. 2005;172:878\u201384.", "ArticleIdList": ["15994467"]}, {"Citation": "Alexis NE, Lay JC, Haczku A, Gong H, Linn W, Hazucha MJ, et al. Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers. Environ Health Perspect. 2008;116:799\u2013805.", "ArticleIdList": ["PMC2430237", "18560537"]}, {"Citation": "Holz O, J\u00f6rres RA, Timm P, M\u00fccke M, Richter K, Koschyk S, et al. Ozone-induced airway inflammatory changes differ between individuals and are reproducible. Am J Respir Crit Care Med. 1999;159:776\u201384.", "ArticleIdList": ["10051250"]}], "ReferenceList": []}], "History": [{"Year": "2015", "Month": "3", "Day": "13"}, {"Year": "2015", "Month": "7", "Day": "24"}, {"Year": "2015", "Month": "8", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2015", "Month": "8", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "6", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2015", "Month": "8", "Day": "12"}], "PublicationStatus": "epublish", "ArticleIdList": ["26265479", "PMC4533952", "10.1186/s40360-015-0021-1", "10.1186/s40360-015-0021-1"]}}], "PubmedBookArticle": []}